What's new

Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 11, Status: Authorised

Feb 14, 2025 - 16:42
 0
Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 11, Status: Authorised
Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 11, Status: Authorised
Read More

Tags:

Previous Article

Spirit Airlines Rejects Frontier Airlines’ Revised Acquisition Offer, Focuses on...

Next Article

Burberry unveils its Summer 2025 Campaign, ‘It’s Always Burberry Weather: London...

Related Posts

Human medicines European public assessment report (EPAR): Remicade, infliximab, Date of authorisation: 13/08/1999, Revision: 67, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 27, 2025  0

Human medicines European public assessment report (EPAR): Emadine, emedastine, Date of authorisation: 27/01/1999, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 21, 2025  0

EMEA-003392-PIP01-23

EMEA-003392-PIP01-23

Feb 19, 2025  0